130 related articles for article (PubMed ID: 14674891)
1. Prognostic factors in Sézary syndrome: a study of 28 patients.
Foulc P; N'Guyen JM; Dréno B
Br J Dermatol; 2003 Dec; 149(6):1152-8. PubMed ID: 14674891
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
3. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
4. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.
Grange F; Hedelin G; Joly P; Beylot-Barry M; D'Incan M; Delaunay M; Vaillant L; Avril MF; Bosq J; Wechsler J; Dalac S; Grosieux C; Franck N; Esteve E; Michel C; Bodemer C; Vergier B; Laroche L; Bagot M
Blood; 1999 Jun; 93(11):3637-42. PubMed ID: 10339469
[TBL] [Abstract][Full Text] [Related]
6. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases.
Marti RM; Pujol RM; Servitje O; Palou J; Romagosa V; Bordes R; González-Castro J; Miralles J; Gallardo F; Curcó N; Gómez X; Domingo A; Estrach T
Leuk Lymphoma; 2003 Jan; 44(1):59-69. PubMed ID: 12691143
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E; Colome M; Fayad L; Duvic M; Kurzrock R
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):914-24. PubMed ID: 10365922
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous tumor cell load correlates with survival in patients with Sézary syndrome.
Booken N; Nicolay JP; Weiss C; Klemke CD
J Dtsch Dermatol Ges; 2013 Jan; 11(1):67-79. PubMed ID: 23167557
[TBL] [Abstract][Full Text] [Related]
9. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
10. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
12. Sézary syndrome: a study of 176 patients at Mayo Clinic.
Kubica AW; Davis MD; Weaver AL; Killian JM; Pittelkow MR
J Am Acad Dermatol; 2012 Dec; 67(6):1189-99. PubMed ID: 22640839
[TBL] [Abstract][Full Text] [Related]
13. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
[TBL] [Abstract][Full Text] [Related]
14. Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome.
Scala E; Abeni D; Palazzo P; Liso M; Pomponi D; Lombardo G; Picchio MC; Narducci MG; Russo G; Mari A
Int Arch Allergy Immunol; 2012; 157(2):159-67. PubMed ID: 21985996
[TBL] [Abstract][Full Text] [Related]
15. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
16. Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome.
Dreno B; Celerier P; Fleischmann M; Bureau B; Litoux P
Acta Derm Venereol; 1994 Sep; 74(5):355-7. PubMed ID: 7817670
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
18. [New developments in Sézary syndrome].
Caudron A; Marie-Cardine A; Bensussan A; Bagot M
Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
[TBL] [Abstract][Full Text] [Related]
19. Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.
Spicknall KE
Semin Cutan Med Surg; 2018 Mar; 37(1):18-23. PubMed ID: 29719016
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
